South Korea · Delayed Price · Currency is KRW T&R Biofab Statistics
Total Valuation
T&R Biofab has a market cap or net worth of KRW 106.29 billion. The enterprise value is 130.69 billion.
| Market Cap | 106.29B |
| Enterprise Value | 130.69B |
Important Dates
The next estimated earnings date is Tuesday, December 1, 2026.
| Earnings Date | Dec 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
T&R Biofab has 47.66 million shares outstanding. The number of shares has increased by 90.06% in one year.
| Current Share Class | 47.66M |
| Shares Outstanding | 47.66M |
| Shares Change (YoY) | +90.06% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | 14.92% |
| Owned by Institutions (%) | 2.79% |
| Float | 40.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.25 |
| PB Ratio | 5.01 |
| P/TBV Ratio | 5.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.33, with a Debt / Equity ratio of 1.44.
| Current Ratio | 0.33 |
| Quick Ratio | 0.24 |
| Debt / Equity | 1.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | -6.71 |
| Interest Coverage | -1.07 |
Financial Efficiency
Return on equity (ROE) is -127.88% and return on invested capital (ROIC) is -5.41%.
| Return on Equity (ROE) | -127.88% |
| Return on Assets (ROA) | -3.50% |
| Return on Invested Capital (ROIC) | -5.41% |
| Return on Capital Employed (ROCE) | -13.57% |
| Weighted Average Cost of Capital (WACC) | 8.01% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.35 |
| Inventory Turnover | 5.37 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.10% in the last 52 weeks. The beta is 0.44, so T&R Biofab's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +16.10% |
| 50-Day Moving Average | 2,370.00 |
| 200-Day Moving Average | 2,790.74 |
| Relative Strength Index (RSI) | 43.62 |
| Average Volume (20 Days) | 113,411 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, T&R Biofab had revenue of KRW 32.73 billion and -27.71 billion in losses. Loss per share was -614.92.
| Revenue | 32.73B |
| Gross Profit | 10.20B |
| Operating Income | -5.26B |
| Pretax Income | -27.71B |
| Net Income | -27.71B |
| EBITDA | -358.15M |
| EBIT | -5.26B |
| Loss Per Share | -614.92 |
Balance Sheet
The company has 6.13 billion in cash and 30.53 billion in debt, with a net cash position of -24.40 billion or -511.92 per share.
| Cash & Cash Equivalents | 6.13B |
| Total Debt | 30.53B |
| Net Cash | -24.40B |
| Net Cash Per Share | -511.92 |
| Equity (Book Value) | 21.20B |
| Book Value Per Share | 444.90 |
| Working Capital | -36.15B |
Cash Flow
In the last 12 months, operating cash flow was -2.25 billion and capital expenditures -2.30 billion, giving a free cash flow of -4.55 billion.
| Operating Cash Flow | -2.25B |
| Capital Expenditures | -2.30B |
| Depreciation & Amortization | 4.90B |
| Net Borrowing | -25.21B |
| Free Cash Flow | -4.55B |
| FCF Per Share | -95.50 |
Margins
Gross margin is 31.15%, with operating and profit margins of -16.05% and -84.66%.
| Gross Margin | 31.15% |
| Operating Margin | -16.05% |
| Pretax Margin | -84.66% |
| Profit Margin | -84.66% |
| EBITDA Margin | -1.09% |
| EBIT Margin | -16.05% |
| FCF Margin | n/a |
Dividends & Yields
T&R Biofab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -90.06% |
| Shareholder Yield | -90.06% |
| Earnings Yield | -26.07% |
| FCF Yield | -4.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 29, 2025. It was a forward split with a ratio of 1.2.
| Last Split Date | Oct 29, 2025 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
T&R Biofab has an Altman Z-Score of -2.04 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.04 |
| Piotroski F-Score | 3 |